nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ALB—Crohn's disease	0.31	1	CbGaD
Erlotinib—ABCG2—Sulfasalazine—Crohn's disease	0.0662	0.39	CbGbCtD
Erlotinib—CYP3A5—Sulfasalazine—Crohn's disease	0.0367	0.216	CbGbCtD
Erlotinib—ALB—Prednisone—Crohn's disease	0.0365	0.215	CbGbCtD
Erlotinib—ABCB1—Prednisone—Crohn's disease	0.0191	0.112	CbGbCtD
Erlotinib—Obliterative bronchiolitis—Mesalazine—Crohn's disease	0.019	0.0766	CcSEcCtD
Erlotinib—ORM1—bile—Crohn's disease	0.0116	0.0939	CbGeAlD
Erlotinib—CYP3A4—Prednisone—Crohn's disease	0.0114	0.0673	CbGbCtD
Erlotinib—LTK—mouth—Crohn's disease	0.00938	0.0758	CbGeAlD
Erlotinib—Hepatic impairment—Mesalazine—Crohn's disease	0.00865	0.0349	CcSEcCtD
Erlotinib—Vandetanib—RIPK2—Crohn's disease	0.00826	0.85	CrCbGaD
Erlotinib—ULK3—mouth—Crohn's disease	0.0051	0.0412	CbGeAlD
Erlotinib—Uveitis—Azathioprine—Crohn's disease	0.00497	0.0201	CcSEcCtD
Erlotinib—Skin hyperpigmentation—Mercaptopurine—Crohn's disease	0.0049	0.0198	CcSEcCtD
Erlotinib—Nephritis—Mesalazine—Crohn's disease	0.00463	0.0187	CcSEcCtD
Erlotinib—Intestinal perforation—Azathioprine—Crohn's disease	0.00439	0.0177	CcSEcCtD
Erlotinib—NR1I2—digestive system—Crohn's disease	0.00415	0.0335	CbGeAlD
Erlotinib—Haematochezia—Mesalazine—Crohn's disease	0.00392	0.0158	CcSEcCtD
Erlotinib—Rosacea—Prednisone—Crohn's disease	0.00383	0.0155	CcSEcCtD
Erlotinib—Hepatotoxicity—Mercaptopurine—Crohn's disease	0.00377	0.0152	CcSEcCtD
Erlotinib—Interstitial pneumonia—Azathioprine—Crohn's disease	0.00359	0.0145	CcSEcCtD
Erlotinib—TNK1—mammalian vulva—Crohn's disease	0.00347	0.0281	CbGeAlD
Erlotinib—Lung infiltration—Mesalazine—Crohn's disease	0.00337	0.0136	CcSEcCtD
Erlotinib—JAK3—lymphoid tissue—Crohn's disease	0.00336	0.0272	CbGeAlD
Erlotinib—JAK3—digestive system—Crohn's disease	0.00332	0.0268	CbGeAlD
Erlotinib—Ulcerative keratitis—Prednisone—Crohn's disease	0.00331	0.0134	CcSEcCtD
Erlotinib—Interstitial pneumonia—Mesalazine—Crohn's disease	0.00327	0.0132	CcSEcCtD
Erlotinib—ORM1—gall bladder—Crohn's disease	0.00322	0.0261	CbGeAlD
Erlotinib—Hepatocellular injury—Mercaptopurine—Crohn's disease	0.00291	0.0118	CcSEcCtD
Erlotinib—ALB—gall bladder—Crohn's disease	0.00283	0.0228	CbGeAlD
Erlotinib—Foetor hepaticus—Mesalazine—Crohn's disease	0.00278	0.0112	CcSEcCtD
Erlotinib—EGFR—mammalian vulva—Crohn's disease	0.00278	0.0225	CbGeAlD
Erlotinib—Hirsutism—Mesalazine—Crohn's disease	0.00272	0.011	CcSEcCtD
Erlotinib—PIP4K2C—mammalian vulva—Crohn's disease	0.0027	0.0218	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—Crohn's disease	0.00265	0.0214	CbGeAlD
Erlotinib—ULK3—mammalian vulva—Crohn's disease	0.00257	0.0208	CbGeAlD
Erlotinib—Sepsis—Mercaptopurine—Crohn's disease	0.00253	0.0102	CcSEcCtD
Erlotinib—Interstitial lung disease—Azathioprine—Crohn's disease	0.00245	0.0099	CcSEcCtD
Erlotinib—Dermatitis acneiform—Prednisone—Crohn's disease	0.00245	0.00988	CcSEcCtD
Erlotinib—Nail disorder—Mesalazine—Crohn's disease	0.00244	0.00984	CcSEcCtD
Erlotinib—MKNK1—mammalian vulva—Crohn's disease	0.00242	0.0196	CbGeAlD
Erlotinib—LTK—lymph node—Crohn's disease	0.00237	0.0192	CbGeAlD
Erlotinib—Liver disorder—Mesalazine—Crohn's disease	0.00232	0.00936	CcSEcCtD
Erlotinib—SLK—mammalian vulva—Crohn's disease	0.00229	0.0185	CbGeAlD
Erlotinib—ULK3—digestive system—Crohn's disease	0.00226	0.0182	CbGeAlD
Erlotinib—Hepatotoxicity—Azathioprine—Crohn's disease	0.00225	0.00907	CcSEcCtD
Erlotinib—Interstitial lung disease—Mesalazine—Crohn's disease	0.00223	0.00902	CcSEcCtD
Erlotinib—Lung disorder—Mesalazine—Crohn's disease	0.00223	0.00902	CcSEcCtD
Erlotinib—Blister—Mesalazine—Crohn's disease	0.00219	0.00885	CcSEcCtD
Erlotinib—MKNK1—lymphoid tissue—Crohn's disease	0.00215	0.0174	CbGeAlD
Erlotinib—Rigors—Azathioprine—Crohn's disease	0.00213	0.00858	CcSEcCtD
Erlotinib—MKNK1—digestive system—Crohn's disease	0.00212	0.0172	CbGeAlD
Erlotinib—Hepatotoxicity—Mesalazine—Crohn's disease	0.00205	0.00826	CcSEcCtD
Erlotinib—AURKC—lymph node—Crohn's disease	0.00205	0.0165	CbGeAlD
Erlotinib—STK10—mammalian vulva—Crohn's disease	0.00199	0.0161	CbGeAlD
Erlotinib—Rash pustular—Mesalazine—Crohn's disease	0.00198	0.008	CcSEcCtD
Erlotinib—JAK3—lymph node—Crohn's disease	0.00189	0.0153	CbGeAlD
Erlotinib—Acne—Mesalazine—Crohn's disease	0.00188	0.00758	CcSEcCtD
Erlotinib—Tenderness—Mesalazine—Crohn's disease	0.00181	0.00731	CcSEcCtD
Erlotinib—Proteinuria—Mesalazine—Crohn's disease	0.0018	0.00726	CcSEcCtD
Erlotinib—Pancreatitis—Mercaptopurine—Crohn's disease	0.00179	0.00723	CcSEcCtD
Erlotinib—MAP2K5—mammalian vulva—Crohn's disease	0.00178	0.0144	CbGeAlD
Erlotinib—Protein urine present—Mesalazine—Crohn's disease	0.00177	0.00716	CcSEcCtD
Erlotinib—STK10—lymphoid tissue—Crohn's disease	0.00177	0.0143	CbGeAlD
Erlotinib—STK10—digestive system—Crohn's disease	0.00175	0.0141	CbGeAlD
Erlotinib—TNK1—lymph node—Crohn's disease	0.00174	0.0141	CbGeAlD
Erlotinib—Hepatocellular injury—Azathioprine—Crohn's disease	0.00174	0.00701	CcSEcCtD
Erlotinib—Colitis—Azathioprine—Crohn's disease	0.00167	0.00673	CcSEcCtD
Erlotinib—UGT1A1—digestive system—Crohn's disease	0.00165	0.0134	CbGeAlD
Erlotinib—CYP1A1—mouth—Crohn's disease	0.00163	0.0132	CbGeAlD
Erlotinib—Musculoskeletal pain—Mesalazine—Crohn's disease	0.0016	0.00646	CcSEcCtD
Erlotinib—Stomatitis—Mercaptopurine—Crohn's disease	0.00159	0.00641	CcSEcCtD
Erlotinib—Hepatocellular injury—Mesalazine—Crohn's disease	0.00158	0.00638	CcSEcCtD
Erlotinib—Melaena—Mesalazine—Crohn's disease	0.00154	0.00623	CcSEcCtD
Erlotinib—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.00154	0.00622	CcSEcCtD
Erlotinib—ABL1—smooth muscle tissue—Crohn's disease	0.00153	0.0123	CbGeAlD
Erlotinib—Colitis—Mesalazine—Crohn's disease	0.00152	0.00613	CcSEcCtD
Erlotinib—Skin exfoliation—Mesalazine—Crohn's disease	0.00151	0.00609	CcSEcCtD
Erlotinib—ABL1—skin of body—Crohn's disease	0.00151	0.0122	CbGeAlD
Erlotinib—FLT3—lymph node—Crohn's disease	0.00149	0.0121	CbGeAlD
Erlotinib—Neuropathy—Mesalazine—Crohn's disease	0.00148	0.00599	CcSEcCtD
Erlotinib—Dry eye—Mesalazine—Crohn's disease	0.00146	0.00589	CcSEcCtD
Erlotinib—Hirsutism—Prednisone—Crohn's disease	0.00144	0.00581	CcSEcCtD
Erlotinib—ABL2—lymph node—Crohn's disease	0.00143	0.0115	CbGeAlD
Erlotinib—Hepatic failure—Azathioprine—Crohn's disease	0.0014	0.00566	CcSEcCtD
Erlotinib—EGFR—lymph node—Crohn's disease	0.00139	0.0113	CbGeAlD
Erlotinib—ABL1—mammalian vulva—Crohn's disease	0.00137	0.0111	CbGeAlD
Erlotinib—PIP4K2C—lymph node—Crohn's disease	0.00135	0.0109	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—Crohn's disease	0.00129	0.0105	CbGeAlD
Erlotinib—Alopecia—Mercaptopurine—Crohn's disease	0.00129	0.00522	CcSEcCtD
Erlotinib—ULK3—lymph node—Crohn's disease	0.00129	0.0104	CbGeAlD
Erlotinib—Hepatic failure—Mesalazine—Crohn's disease	0.00128	0.00515	CcSEcCtD
Erlotinib—CYP1B1—skin of body—Crohn's disease	0.00128	0.0103	CbGeAlD
Erlotinib—Malnutrition—Mercaptopurine—Crohn's disease	0.00127	0.00514	CcSEcCtD
Erlotinib—Peptic ulcer—Prednisone—Crohn's disease	0.00125	0.00505	CcSEcCtD
Erlotinib—Renal failure acute—Mesalazine—Crohn's disease	0.00124	0.00502	CcSEcCtD
Erlotinib—ABL1—lymphoid tissue—Crohn's disease	0.00122	0.00986	CbGeAlD
Erlotinib—SLCO2B1—digestive system—Crohn's disease	0.00122	0.00983	CbGeAlD
Erlotinib—MKNK1—lymph node—Crohn's disease	0.00121	0.00981	CbGeAlD
Erlotinib—Renal impairment—Mesalazine—Crohn's disease	0.00121	0.00487	CcSEcCtD
Erlotinib—ABL1—digestive system—Crohn's disease	0.00121	0.00974	CbGeAlD
Erlotinib—Dermatitis bullous—Mesalazine—Crohn's disease	0.0012	0.00485	CcSEcCtD
Erlotinib—Myopathy—Prednisone—Crohn's disease	0.00119	0.00481	CcSEcCtD
Erlotinib—SLK—lymph node—Crohn's disease	0.00115	0.00929	CbGeAlD
Erlotinib—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.00115	0.00463	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Azathioprine—Crohn's disease	0.00113	0.00458	CcSEcCtD
Erlotinib—Arthralgia—Mercaptopurine—Crohn's disease	0.00108	0.00438	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00108	0.00435	CcSEcCtD
Erlotinib—Pancreatitis—Azathioprine—Crohn's disease	0.00107	0.00431	CcSEcCtD
Erlotinib—Dry skin—Mesalazine—Crohn's disease	0.00105	0.00425	CcSEcCtD
Erlotinib—Oedema—Mercaptopurine—Crohn's disease	0.00104	0.0042	CcSEcCtD
Erlotinib—CYP1B1—lymphoid tissue—Crohn's disease	0.00103	0.00835	CbGeAlD
Erlotinib—CYP1B1—digestive system—Crohn's disease	0.00102	0.00825	CbGeAlD
Erlotinib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00102	0.00411	CcSEcCtD
Erlotinib—Gastritis—Mesalazine—Crohn's disease	0.00102	0.0041	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00101	0.00409	CcSEcCtD
Erlotinib—Skin disorder—Mercaptopurine—Crohn's disease	0.00101	0.00407	CcSEcCtD
Erlotinib—STK10—lymph node—Crohn's disease	0.000999	0.00808	CbGeAlD
Erlotinib—Acne—Prednisone—Crohn's disease	0.000994	0.00401	CcSEcCtD
Erlotinib—Dysphagia—Mesalazine—Crohn's disease	0.000991	0.004	CcSEcCtD
Erlotinib—Anorexia—Mercaptopurine—Crohn's disease	0.00099	0.004	CcSEcCtD
Erlotinib—Pneumonia—Azathioprine—Crohn's disease	0.000976	0.00394	CcSEcCtD
Erlotinib—Pancreatitis—Mesalazine—Crohn's disease	0.000972	0.00393	CcSEcCtD
Erlotinib—Infestation NOS—Azathioprine—Crohn's disease	0.000971	0.00392	CcSEcCtD
Erlotinib—Infestation—Azathioprine—Crohn's disease	0.000971	0.00392	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000962	0.00389	CcSEcCtD
Erlotinib—CYP1A1—epithelium—Crohn's disease	0.000948	0.00767	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000946	0.00382	CcSEcCtD
Erlotinib—Neutropenia—Mesalazine—Crohn's disease	0.000927	0.00374	CcSEcCtD
Erlotinib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000918	0.00371	CcSEcCtD
Erlotinib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000903	0.00365	CcSEcCtD
Erlotinib—CYP1A1—skin of body—Crohn's disease	0.000902	0.00729	CbGeAlD
Erlotinib—Weight decreased—Mesalazine—Crohn's disease	0.000897	0.00362	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000897	0.00362	CcSEcCtD
Erlotinib—MAP2K5—lymph node—Crohn's disease	0.000892	0.00721	CbGeAlD
Erlotinib—Pneumonia—Mesalazine—Crohn's disease	0.000889	0.00359	CcSEcCtD
Erlotinib—Infestation—Mesalazine—Crohn's disease	0.000884	0.00357	CcSEcCtD
Erlotinib—Infestation NOS—Mesalazine—Crohn's disease	0.000884	0.00357	CcSEcCtD
Erlotinib—Depression—Mesalazine—Crohn's disease	0.000881	0.00356	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.000876	0.00354	CcSEcCtD
Erlotinib—Haemoglobin—Azathioprine—Crohn's disease	0.000876	0.00354	CcSEcCtD
Erlotinib—Haemorrhage—Azathioprine—Crohn's disease	0.000871	0.00352	CcSEcCtD
Erlotinib—Renal failure—Mesalazine—Crohn's disease	0.000869	0.00351	CcSEcCtD
Erlotinib—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000867	0.0035	CcSEcCtD
Erlotinib—ABCG2—mammalian vulva—Crohn's disease	0.000866	0.00701	CbGeAlD
Erlotinib—Stomatitis—Mesalazine—Crohn's disease	0.000862	0.00348	CcSEcCtD
Erlotinib—Conjunctivitis—Mesalazine—Crohn's disease	0.000859	0.00347	CcSEcCtD
Erlotinib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000836	0.00338	CcSEcCtD
Erlotinib—Epistaxis—Mesalazine—Crohn's disease	0.000834	0.00337	CcSEcCtD
Erlotinib—Erythema multiforme—Azathioprine—Crohn's disease	0.000824	0.00333	CcSEcCtD
Erlotinib—CYP1A1—mammalian vulva—Crohn's disease	0.000823	0.00665	CbGeAlD
Erlotinib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000821	0.00332	CcSEcCtD
Erlotinib—Skin exfoliation—Prednisone—Crohn's disease	0.000798	0.00322	CcSEcCtD
Erlotinib—Haemoglobin—Mesalazine—Crohn's disease	0.000798	0.00322	CcSEcCtD
Erlotinib—Haemorrhage—Mesalazine—Crohn's disease	0.000794	0.0032	CcSEcCtD
Erlotinib—Hepatitis—Mesalazine—Crohn's disease	0.000794	0.0032	CcSEcCtD
Erlotinib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000785	0.00317	CcSEcCtD
Erlotinib—Neuropathy—Prednisone—Crohn's disease	0.000785	0.00317	CcSEcCtD
Erlotinib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000784	0.00316	CcSEcCtD
Erlotinib—Chills—Azathioprine—Crohn's disease	0.000782	0.00316	CcSEcCtD
Erlotinib—Connective tissue disorder—Mesalazine—Crohn's disease	0.00078	0.00315	CcSEcCtD
Erlotinib—Arrhythmia—Azathioprine—Crohn's disease	0.000778	0.00314	CcSEcCtD
Erlotinib—Urethral disorder—Mesalazine—Crohn's disease	0.000778	0.00314	CcSEcCtD
Erlotinib—Alopecia—Azathioprine—Crohn's disease	0.00077	0.00311	CcSEcCtD
Erlotinib—Erythema multiforme—Mesalazine—Crohn's disease	0.00075	0.00303	CcSEcCtD
Erlotinib—Vandetanib—ALB—Crohn's disease	0.00075	0.0771	CrCbGaD
Erlotinib—Eye disorder—Mesalazine—Crohn's disease	0.000742	0.00299	CcSEcCtD
Erlotinib—CYP1A2—digestive system—Crohn's disease	0.000731	0.00591	CbGeAlD
Erlotinib—Sepsis—Prednisone—Crohn's disease	0.000726	0.00293	CcSEcCtD
Erlotinib—ORM1—lymph node—Crohn's disease	0.000724	0.00586	CbGeAlD
Erlotinib—CYP1A1—digestive system—Crohn's disease	0.000721	0.00583	CbGeAlD
Erlotinib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000715	0.00289	CcSEcCtD
Erlotinib—Gefitinib—ALB—Crohn's disease	0.000712	0.0732	CrCbGaD
Erlotinib—Chills—Mesalazine—Crohn's disease	0.000712	0.00288	CcSEcCtD
Erlotinib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000711	0.00287	CcSEcCtD
Erlotinib—CYP3A5—digestive system—Crohn's disease	0.000705	0.0057	CbGeAlD
Erlotinib—Alopecia—Mesalazine—Crohn's disease	0.000701	0.00283	CcSEcCtD
Erlotinib—Mental disorder—Mesalazine—Crohn's disease	0.000695	0.00281	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—Crohn's disease	0.000694	0.00561	CbGeAlD
Erlotinib—Erythema—Mesalazine—Crohn's disease	0.000691	0.00279	CcSEcCtD
Erlotinib—ABL1—lymph node—Crohn's disease	0.000688	0.00557	CbGeAlD
Erlotinib—Flatulence—Mesalazine—Crohn's disease	0.000681	0.00275	CcSEcCtD
Erlotinib—Back pain—Mesalazine—Crohn's disease	0.000668	0.0027	CcSEcCtD
Erlotinib—Vomiting—Mercaptopurine—Crohn's disease	0.000661	0.00267	CcSEcCtD
Erlotinib—Rash—Mercaptopurine—Crohn's disease	0.000655	0.00265	CcSEcCtD
Erlotinib—Dermatitis—Mercaptopurine—Crohn's disease	0.000654	0.00264	CcSEcCtD
Erlotinib—Myalgia—Azathioprine—Crohn's disease	0.000646	0.00261	CcSEcCtD
Erlotinib—Arthralgia—Azathioprine—Crohn's disease	0.000646	0.00261	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000641	0.00259	CcSEcCtD
Erlotinib—ALB—lymph node—Crohn's disease	0.000635	0.00514	CbGeAlD
Erlotinib—Syncope—Mesalazine—Crohn's disease	0.00062	0.0025	CcSEcCtD
Erlotinib—Nausea—Mercaptopurine—Crohn's disease	0.000617	0.00249	CcSEcCtD
Erlotinib—Infection—Azathioprine—Crohn's disease	0.000615	0.00248	CcSEcCtD
Erlotinib—Loss of consciousness—Mesalazine—Crohn's disease	0.000607	0.00245	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000607	0.00245	CcSEcCtD
Erlotinib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000606	0.00245	CcSEcCtD
Erlotinib—Cough—Mesalazine—Crohn's disease	0.000603	0.00243	CcSEcCtD
Erlotinib—Skin disorder—Azathioprine—Crohn's disease	0.000601	0.00243	CcSEcCtD
Erlotinib—Arthralgia—Mesalazine—Crohn's disease	0.000588	0.00238	CcSEcCtD
Erlotinib—Chest pain—Mesalazine—Crohn's disease	0.000588	0.00238	CcSEcCtD
Erlotinib—Myalgia—Mesalazine—Crohn's disease	0.000588	0.00238	CcSEcCtD
Erlotinib—Anxiety—Mesalazine—Crohn's disease	0.000586	0.00237	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000584	0.00236	CcSEcCtD
Erlotinib—CYP1B1—lymph node—Crohn's disease	0.000583	0.00471	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000564	0.00228	CcSEcCtD
Erlotinib—Oedema—Mesalazine—Crohn's disease	0.000564	0.00228	CcSEcCtD
Erlotinib—Infection—Mesalazine—Crohn's disease	0.00056	0.00226	CcSEcCtD
Erlotinib—Dry skin—Prednisone—Crohn's disease	0.000556	0.00225	CcSEcCtD
Erlotinib—Shock—Mesalazine—Crohn's disease	0.000555	0.00224	CcSEcCtD
Erlotinib—Nervous system disorder—Mesalazine—Crohn's disease	0.000553	0.00223	CcSEcCtD
Erlotinib—Hypokalaemia—Prednisone—Crohn's disease	0.000552	0.00223	CcSEcCtD
Erlotinib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000552	0.00223	CcSEcCtD
Erlotinib—Skin disorder—Mesalazine—Crohn's disease	0.000548	0.00221	CcSEcCtD
Erlotinib—Anorexia—Mesalazine—Crohn's disease	0.000537	0.00217	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000535	0.00216	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000534	0.00216	CcSEcCtD
Erlotinib—CYP3A4—digestive system—Crohn's disease	0.000529	0.00428	CbGeAlD
Erlotinib—CYP2D6—digestive system—Crohn's disease	0.000521	0.00421	CbGeAlD
Erlotinib—Pancreatitis—Prednisone—Crohn's disease	0.000514	0.00208	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000514	0.00207	CcSEcCtD
Erlotinib—Insomnia—Mesalazine—Crohn's disease	0.00051	0.00206	CcSEcCtD
Erlotinib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000506	0.00204	CcSEcCtD
Erlotinib—Dyspnoea—Mesalazine—Crohn's disease	0.000503	0.00203	CcSEcCtD
Erlotinib—Dyspepsia—Mesalazine—Crohn's disease	0.000496	0.002	CcSEcCtD
Erlotinib—ABCB1—epithelium—Crohn's disease	0.000493	0.00398	CbGeAlD
Erlotinib—Neutropenia—Prednisone—Crohn's disease	0.000491	0.00198	CcSEcCtD
Erlotinib—Decreased appetite—Mesalazine—Crohn's disease	0.00049	0.00198	CcSEcCtD
Erlotinib—Abdominal pain—Azathioprine—Crohn's disease	0.000489	0.00198	CcSEcCtD
Erlotinib—Body temperature increased—Azathioprine—Crohn's disease	0.000489	0.00198	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000487	0.00197	CcSEcCtD
Erlotinib—Fatigue—Mesalazine—Crohn's disease	0.000486	0.00196	CcSEcCtD
Erlotinib—Pain—Mesalazine—Crohn's disease	0.000482	0.00195	CcSEcCtD
Erlotinib—Constipation—Mesalazine—Crohn's disease	0.000482	0.00195	CcSEcCtD
Erlotinib—Weight decreased—Prednisone—Crohn's disease	0.000475	0.00192	CcSEcCtD
Erlotinib—Depression—Prednisone—Crohn's disease	0.000466	0.00188	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—Crohn's disease	0.000461	0.00186	CcSEcCtD
Erlotinib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000461	0.00186	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—Crohn's disease	0.000458	0.00185	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—Crohn's disease	0.000458	0.00185	CcSEcCtD
Erlotinib—Abdominal pain—Mesalazine—Crohn's disease	0.000446	0.0018	CcSEcCtD
Erlotinib—Body temperature increased—Mesalazine—Crohn's disease	0.000446	0.0018	CcSEcCtD
Erlotinib—ABCG2—lymph node—Crohn's disease	0.000434	0.00351	CbGeAlD
Erlotinib—ABCB1—mammalian vulva—Crohn's disease	0.000427	0.00345	CbGeAlD
Erlotinib—Diarrhoea—Azathioprine—Crohn's disease	0.000424	0.00171	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—Crohn's disease	0.000422	0.0017	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—Crohn's disease	0.00042	0.0017	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—Crohn's disease	0.000413	0.00167	CcSEcCtD
Erlotinib—CYP1A1—lymph node—Crohn's disease	0.000412	0.00333	CbGeAlD
Erlotinib—Dizziness—Azathioprine—Crohn's disease	0.000409	0.00165	CcSEcCtD
Erlotinib—Asthenia—Mesalazine—Crohn's disease	0.000405	0.00163	CcSEcCtD
Erlotinib—Pruritus—Mesalazine—Crohn's disease	0.000399	0.00161	CcSEcCtD
Erlotinib—Vomiting—Azathioprine—Crohn's disease	0.000394	0.00159	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—Crohn's disease	0.000392	0.00158	CcSEcCtD
Erlotinib—Rash—Azathioprine—Crohn's disease	0.00039	0.00158	CcSEcCtD
Erlotinib—Dermatitis—Azathioprine—Crohn's disease	0.00039	0.00157	CcSEcCtD
Erlotinib—Headache—Azathioprine—Crohn's disease	0.000388	0.00157	CcSEcCtD
Erlotinib—Diarrhoea—Mesalazine—Crohn's disease	0.000386	0.00156	CcSEcCtD
Erlotinib—ABCB1—lymphoid tissue—Crohn's disease	0.000379	0.00307	CbGeAlD
Erlotinib—Arrhythmia—Prednisone—Crohn's disease	0.000375	0.00151	CcSEcCtD
Erlotinib—ABCB1—digestive system—Crohn's disease	0.000375	0.00303	CbGeAlD
Erlotinib—Dizziness—Mesalazine—Crohn's disease	0.000373	0.00151	CcSEcCtD
Erlotinib—Alopecia—Prednisone—Crohn's disease	0.000371	0.0015	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—Crohn's disease	0.000368	0.00149	CcSEcCtD
Erlotinib—Nausea—Azathioprine—Crohn's disease	0.000368	0.00148	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—Crohn's disease	0.000366	0.00148	CcSEcCtD
Erlotinib—Erythema—Prednisone—Crohn's disease	0.000366	0.00148	CcSEcCtD
Erlotinib—Vomiting—Mesalazine—Crohn's disease	0.000358	0.00145	CcSEcCtD
Erlotinib—Rash—Mesalazine—Crohn's disease	0.000356	0.00144	CcSEcCtD
Erlotinib—Dermatitis—Mesalazine—Crohn's disease	0.000355	0.00143	CcSEcCtD
Erlotinib—Headache—Mesalazine—Crohn's disease	0.000353	0.00143	CcSEcCtD
Erlotinib—Nausea—Mesalazine—Crohn's disease	0.000335	0.00135	CcSEcCtD
Erlotinib—Syncope—Prednisone—Crohn's disease	0.000328	0.00132	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—Crohn's disease	0.000321	0.0013	CcSEcCtD
Erlotinib—Myalgia—Prednisone—Crohn's disease	0.000311	0.00126	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—Crohn's disease	0.000311	0.00126	CcSEcCtD
Erlotinib—Anxiety—Prednisone—Crohn's disease	0.00031	0.00125	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000309	0.00125	CcSEcCtD
Erlotinib—Oedema—Prednisone—Crohn's disease	0.000298	0.0012	CcSEcCtD
Erlotinib—Infection—Prednisone—Crohn's disease	0.000296	0.0012	CcSEcCtD
Erlotinib—Shock—Prednisone—Crohn's disease	0.000293	0.00119	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—Crohn's disease	0.000293	0.00118	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—Crohn's disease	0.00029	0.00117	CcSEcCtD
Erlotinib—Anorexia—Prednisone—Crohn's disease	0.000284	0.00115	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000272	0.0011	CcSEcCtD
Erlotinib—Insomnia—Prednisone—Crohn's disease	0.00027	0.00109	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—Crohn's disease	0.000263	0.00106	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—Crohn's disease	0.000259	0.00105	CcSEcCtD
Erlotinib—Fatigue—Prednisone—Crohn's disease	0.000257	0.00104	CcSEcCtD
Erlotinib—Constipation—Prednisone—Crohn's disease	0.000255	0.00103	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—Crohn's disease	0.000244	0.000985	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—Crohn's disease	0.000236	0.000952	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—Crohn's disease	0.000236	0.000952	CcSEcCtD
Erlotinib—ABCB1—lymph node—Crohn's disease	0.000214	0.00173	CbGeAlD
Erlotinib—Asthenia—Prednisone—Crohn's disease	0.000214	0.000864	CcSEcCtD
Erlotinib—Pruritus—Prednisone—Crohn's disease	0.000211	0.000852	CcSEcCtD
Erlotinib—Diarrhoea—Prednisone—Crohn's disease	0.000204	0.000824	CcSEcCtD
Erlotinib—Dizziness—Prednisone—Crohn's disease	0.000197	0.000797	CcSEcCtD
Erlotinib—Vomiting—Prednisone—Crohn's disease	0.00019	0.000766	CcSEcCtD
Erlotinib—Rash—Prednisone—Crohn's disease	0.000188	0.00076	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—Crohn's disease	0.000188	0.000759	CcSEcCtD
Erlotinib—Headache—Prednisone—Crohn's disease	0.000187	0.000755	CcSEcCtD
Erlotinib—Nausea—Prednisone—Crohn's disease	0.000177	0.000716	CcSEcCtD
Erlotinib—EGFR—Axon guidance—JAK2—Crohn's disease	4.23e-05	0.000303	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—IL6—Crohn's disease	4.22e-05	0.000302	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—UBE2D1—Crohn's disease	4.2e-05	0.000301	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—TLR4—Crohn's disease	4.2e-05	0.000301	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TNF—Crohn's disease	4.2e-05	0.0003	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—FADS1—Crohn's disease	4.19e-05	0.0003	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GCKR—Crohn's disease	4.16e-05	0.000298	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—Crohn's disease	4.12e-05	0.000295	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	4.1e-05	0.000294	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—Crohn's disease	4.09e-05	0.000293	CbGpPWpGaD
Erlotinib—ABL1—Immune System—UBE2D1—Crohn's disease	4.08e-05	0.000292	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RIPK2—Crohn's disease	4.08e-05	0.000292	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—TYK2—Crohn's disease	4.07e-05	0.000292	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	4.06e-05	0.000291	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—IL6—Crohn's disease	4.04e-05	0.000289	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTPN2—Crohn's disease	4.02e-05	0.000288	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GPR65—Crohn's disease	3.99e-05	0.000286	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RBX1—Crohn's disease	3.98e-05	0.000285	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—IL6—Crohn's disease	3.97e-05	0.000285	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL3—Crohn's disease	3.97e-05	0.000285	CbGpPWpGaD
Erlotinib—ABL1—Immune System—RIPK2—Crohn's disease	3.96e-05	0.000283	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ITGA4—Crohn's disease	3.96e-05	0.000283	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	3.92e-05	0.000281	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GPX4—Crohn's disease	3.92e-05	0.000281	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CXCL8—Crohn's disease	3.91e-05	0.00028	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PLA2G4F—Crohn's disease	3.9e-05	0.000279	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—JAK2—Crohn's disease	3.89e-05	0.000278	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	3.87e-05	0.000277	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL3—Crohn's disease	3.86e-05	0.000276	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTMR3—Crohn's disease	3.85e-05	0.000276	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RASGRP1—Crohn's disease	3.84e-05	0.000275	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	3.8e-05	0.000272	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—Crohn's disease	3.8e-05	0.000272	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GCKR—Crohn's disease	3.79e-05	0.000271	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—Crohn's disease	3.78e-05	0.00027	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—Crohn's disease	3.76e-05	0.000269	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CRP—Crohn's disease	3.74e-05	0.000268	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—Crohn's disease	3.74e-05	0.000268	CbGpPWpGaD
Erlotinib—ABL1—Immune System—RASGRP1—Crohn's disease	3.73e-05	0.000267	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—ALB—Crohn's disease	3.73e-05	0.000267	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD79A—Crohn's disease	3.72e-05	0.000266	CbGpPWpGaD
Erlotinib—JAK3—Immune System—TYK2—Crohn's disease	3.72e-05	0.000266	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—ITGA4—Crohn's disease	3.72e-05	0.000266	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TYK2—Crohn's disease	3.7e-05	0.000265	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SMAD3—Crohn's disease	3.69e-05	0.000264	CbGpPWpGaD
Erlotinib—EGFR—Disease—HSPA1B—Crohn's disease	3.67e-05	0.000263	CbGpPWpGaD
Erlotinib—EGFR—Disease—RBX1—Crohn's disease	3.67e-05	0.000263	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TAB1—Crohn's disease	3.65e-05	0.000262	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTMR3—Crohn's disease	3.64e-05	0.000261	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL3—Crohn's disease	3.62e-05	0.000259	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL3—Crohn's disease	3.61e-05	0.000258	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NOD2—Crohn's disease	3.59e-05	0.000257	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TLR4—Crohn's disease	3.59e-05	0.000257	CbGpPWpGaD
Erlotinib—JAK3—Immune System—JAK2—Crohn's disease	3.55e-05	0.000254	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CXCL8—Crohn's disease	3.55e-05	0.000254	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—Crohn's disease	3.54e-05	0.000254	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—JAK2—Crohn's disease	3.53e-05	0.000253	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—Crohn's disease	3.52e-05	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	3.52e-05	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—Crohn's disease	3.52e-05	0.000252	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—RASGRP1—Crohn's disease	3.5e-05	0.000251	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—RASGRP1—Crohn's disease	3.49e-05	0.00025	CbGpPWpGaD
Erlotinib—EGFR—Immune System—UBE2D1—Crohn's disease	3.49e-05	0.00025	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—Crohn's disease	3.49e-05	0.00025	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IFNG—Crohn's disease	3.48e-05	0.000249	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SOCS1—Crohn's disease	3.48e-05	0.000249	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—JAK2—Crohn's disease	3.47e-05	0.000248	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—Crohn's disease	3.46e-05	0.000247	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—Crohn's disease	3.44e-05	0.000246	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—STAT3—Crohn's disease	3.43e-05	0.000246	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PLA2G4F—Crohn's disease	3.42e-05	0.000245	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2RA—Crohn's disease	3.42e-05	0.000245	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SOCS1—Crohn's disease	3.38e-05	0.000242	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ITGA4—Crohn's disease	3.38e-05	0.000242	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RIPK2—Crohn's disease	3.38e-05	0.000242	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—Crohn's disease	3.37e-05	0.000241	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTMR3—Crohn's disease	3.34e-05	0.000239	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTMR3—Crohn's disease	3.32e-05	0.000238	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—JAK2—Crohn's disease	3.31e-05	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ICAM1—Crohn's disease	3.3e-05	0.000236	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL3—Crohn's disease	3.3e-05	0.000236	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—TYK2—Crohn's disease	3.27e-05	0.000234	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	3.22e-05	0.000231	CbGpPWpGaD
Erlotinib—EGFR—Disease—UBE2D1—Crohn's disease	3.22e-05	0.000231	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TYK2—Crohn's disease	3.19e-05	0.000228	CbGpPWpGaD
Erlotinib—MKNK1—Disease—STAT3—Crohn's disease	3.19e-05	0.000228	CbGpPWpGaD
Erlotinib—EGFR—Immune System—RASGRP1—Crohn's disease	3.19e-05	0.000228	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD79A—Crohn's disease	3.18e-05	0.000228	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TYK2—Crohn's disease	3.16e-05	0.000227	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TAB1—Crohn's disease	3.12e-05	0.000223	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—JAK2—Crohn's disease	3.12e-05	0.000223	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	3.12e-05	0.000223	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1B—Crohn's disease	3.11e-05	0.000223	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.07e-05	0.00022	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NOD2—Crohn's disease	3.07e-05	0.00022	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL18—Crohn's disease	3.05e-05	0.000218	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—JAK2—Crohn's disease	3.04e-05	0.000218	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—JAK2—Crohn's disease	3.02e-05	0.000216	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	3.01e-05	0.000216	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SMAD3—Crohn's disease	3.01e-05	0.000215	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—FADS1—Crohn's disease	3e-05	0.000215	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	2.98e-05	0.000213	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—Crohn's disease	2.96e-05	0.000212	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTMR3—Crohn's disease	2.91e-05	0.000208	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SOCS1—Crohn's disease	2.89e-05	0.000207	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR6—Crohn's disease	2.84e-05	0.000204	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—FADS1—Crohn's disease	2.84e-05	0.000203	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX4—Crohn's disease	2.81e-05	0.000201	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TYK2—Crohn's disease	2.8e-05	0.0002	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2RA—Crohn's disease	2.78e-05	0.000199	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL8—Crohn's disease	2.78e-05	0.000199	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTMR3—Crohn's disease	2.74e-05	0.000196	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	2.73e-05	0.000195	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GCKR—Crohn's disease	2.71e-05	0.000194	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2RA—Crohn's disease	2.7e-05	0.000194	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—JAK2—Crohn's disease	2.67e-05	0.000191	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX4—Crohn's disease	2.66e-05	0.00019	CbGpPWpGaD
Erlotinib—JAK3—Immune System—STAT3—Crohn's disease	2.61e-05	0.000187	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	2.6e-05	0.000186	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL18—Crohn's disease	2.6e-05	0.000186	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—FADS1—Crohn's disease	2.6e-05	0.000186	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—STAT3—Crohn's disease	2.59e-05	0.000186	CbGpPWpGaD
Erlotinib—ALB—Metabolism—FADS1—Crohn's disease	2.59e-05	0.000185	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—ALB—Crohn's disease	2.57e-05	0.000184	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RBX1—Crohn's disease	2.57e-05	0.000184	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GCKR—Crohn's disease	2.56e-05	0.000184	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CRP—Crohn's disease	2.55e-05	0.000183	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2RA—Crohn's disease	2.54e-05	0.000182	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—Crohn's disease	2.54e-05	0.000182	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2RA—Crohn's disease	2.53e-05	0.000181	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—Crohn's disease	2.53e-05	0.000181	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTGER4—Crohn's disease	2.5e-05	0.000179	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TLR4—Crohn's disease	2.45e-05	0.000175	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX4—Crohn's disease	2.43e-05	0.000174	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—Crohn's disease	2.43e-05	0.000174	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX4—Crohn's disease	2.42e-05	0.000173	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TYK2—Crohn's disease	2.41e-05	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—Crohn's disease	2.4e-05	0.000172	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GCKR—Crohn's disease	2.35e-05	0.000168	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ICAM1—Crohn's disease	2.34e-05	0.000168	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GCKR—Crohn's disease	2.34e-05	0.000167	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTMR3—Crohn's disease	2.32e-05	0.000166	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2RA—Crohn's disease	2.31e-05	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Disease—SMAD3—Crohn's disease	2.3e-05	0.000165	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—JAK2—Crohn's disease	2.3e-05	0.000164	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—FADS1—Crohn's disease	2.27e-05	0.000162	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—UBE2D1—Crohn's disease	2.26e-05	0.000161	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—Crohn's disease	2.24e-05	0.000161	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—STAT3—Crohn's disease	2.23e-05	0.00016	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—Crohn's disease	2.23e-05	0.00016	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—STAT3—Crohn's disease	2.22e-05	0.000159	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RIPK2—Crohn's disease	2.19e-05	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CRP—Crohn's disease	2.18e-05	0.000156	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—Crohn's disease	2.17e-05	0.000155	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—FADS1—Crohn's disease	2.13e-05	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL3—Crohn's disease	2.13e-05	0.000153	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX4—Crohn's disease	2.12e-05	0.000152	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.11e-05	0.000151	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL8—Crohn's disease	2.09e-05	0.00015	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TLR4—Crohn's disease	2.09e-05	0.00015	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.07e-05	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RASGRP1—Crohn's disease	2.06e-05	0.000148	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GCKR—Crohn's disease	2.05e-05	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ICAM1—Crohn's disease	2e-05	0.000143	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX4—Crohn's disease	2e-05	0.000143	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—Crohn's disease	1.99e-05	0.000143	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TYK2—Crohn's disease	1.96e-05	0.00014	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GCKR—Crohn's disease	1.93e-05	0.000138	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—Crohn's disease	1.92e-05	0.000137	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TYK2—Crohn's disease	1.91e-05	0.000136	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—JAK2—Crohn's disease	1.87e-05	0.000134	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SOCS1—Crohn's disease	1.87e-05	0.000134	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.83e-05	0.000131	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—Crohn's disease	1.82e-05	0.00013	CbGpPWpGaD
Erlotinib—ABL1—Immune System—JAK2—Crohn's disease	1.82e-05	0.00013	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—Crohn's disease	1.81e-05	0.00013	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FADS1—Crohn's disease	1.81e-05	0.000129	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTMR3—Crohn's disease	1.79e-05	0.000128	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNG—Crohn's disease	1.78e-05	0.000128	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TYK2—Crohn's disease	1.78e-05	0.000128	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—Crohn's disease	1.72e-05	0.000123	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—Crohn's disease	1.71e-05	0.000122	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—JAK2—Crohn's disease	1.71e-05	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—JAK2—Crohn's disease	1.7e-05	0.000122	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX4—Crohn's disease	1.69e-05	0.000121	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—STAT3—Crohn's disease	1.68e-05	0.000121	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.68e-05	0.00012	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GCKR—Crohn's disease	1.64e-05	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TYK2—Crohn's disease	1.63e-05	0.000117	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMAD3—Crohn's disease	1.61e-05	0.000116	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.6e-05	0.000115	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—Crohn's disease	1.6e-05	0.000115	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—Crohn's disease	1.59e-05	0.000114	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—Crohn's disease	1.56e-05	0.000112	CbGpPWpGaD
Erlotinib—EGFR—Immune System—JAK2—Crohn's disease	1.55e-05	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—Crohn's disease	1.55e-05	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—Crohn's disease	1.55e-05	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNG—Crohn's disease	1.52e-05	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Disease—TYK2—Crohn's disease	1.5e-05	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2RA—Crohn's disease	1.49e-05	0.000107	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—Crohn's disease	1.47e-05	0.000105	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.47e-05	0.000105	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.46e-05	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Disease—JAK2—Crohn's disease	1.43e-05	0.000103	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ALB—Crohn's disease	1.42e-05	0.000102	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FADS1—Crohn's disease	1.4e-05	9.99e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.39e-05	9.97e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT3—Crohn's disease	1.37e-05	9.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—Crohn's disease	1.37e-05	9.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—Crohn's disease	1.36e-05	9.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—Crohn's disease	1.36e-05	9.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—Crohn's disease	1.35e-05	9.66e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT3—Crohn's disease	1.33e-05	9.55e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ALB—Crohn's disease	1.33e-05	9.49e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX4—Crohn's disease	1.31e-05	9.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GCKR—Crohn's disease	1.26e-05	9.04e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—Crohn's disease	1.24e-05	8.9e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ALB—Crohn's disease	1.21e-05	8.63e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—Crohn's disease	1.18e-05	8.43e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.17e-05	8.37e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—Crohn's disease	1.16e-05	8.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT3—Crohn's disease	1.14e-05	8.16e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—Crohn's disease	1.05e-05	7.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TYK2—Crohn's disease	1.05e-05	7.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—STAT3—Crohn's disease	1.05e-05	7.53e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.02e-05	7.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—JAK2—Crohn's disease	1e-05	7.19e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—Crohn's disease	9.59e-06	6.87e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—Crohn's disease	9.32e-06	6.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—Crohn's disease	9.16e-06	6.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—Crohn's disease	8.71e-06	6.24e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ALB—Crohn's disease	8.64e-06	6.19e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ALB—Crohn's disease	8.16e-06	5.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—Crohn's disease	7.96e-06	5.7e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—Crohn's disease	7.56e-06	5.41e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ALB—Crohn's disease	7.48e-06	5.36e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT3—Crohn's disease	7.37e-06	5.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—Crohn's disease	7.35e-06	5.26e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—Crohn's disease	7.14e-06	5.11e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—Crohn's disease	6.55e-06	4.69e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ALB—Crohn's disease	6.52e-06	4.67e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—Crohn's disease	6.51e-06	4.66e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ALB—Crohn's disease	6.14e-06	4.4e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—Crohn's disease	5.7e-06	4.08e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—Crohn's disease	5.37e-06	3.85e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ALB—Crohn's disease	5.2e-06	3.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—Crohn's disease	5.15e-06	3.69e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—Crohn's disease	4.55e-06	3.26e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ALB—Crohn's disease	4.02e-06	2.88e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—Crohn's disease	3.51e-06	2.52e-05	CbGpPWpGaD
